This is the first study to indicate that the NAR could serve as a mediator between H. pylori infection and the risk of MASLD; specifically, whether decreasing the NAR through the elimination of H. pylori reduces the risk of MASLD could be studied, and new therapeutic targets for the prevention and treatment of MASLD could be identified. Here, CPSF4 is linked to metabolic dysfunction-associated steatotic liver disease.